Cardiovascular risks associated with second-line oral antidiabetic agents added to metformin in patients with Type 2 diabetes: A nationwide cohort study

Diabetic Medicine

Volumn 32, Issue 11, 2015, Pages 1460-1469

  Chang, Y C ^a,b,c   Chuang, L M ^a,b,c   Lin, J W ^b,c   Chen, S T ^a   Lai, M S ^a   Chang, C H ^a,b,c  

^a NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^c NATIONAL TAIWAN UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA GLUCOSIDASE INHIBITOR; DIPEPTIDYL PEPTIDASE IV INHIBITOR; METFORMIN; METFORMIN PLUS PIOGLITAZONE; ORAL ANTIDIABETIC AGENT; PIOGLITAZONE; SULFONYLUREA; ANTIDIABETIC AGENT; GLYCOSIDASE INHIBITOR;

ACUTE HEART INFARCTION; ADD ON THERAPY; ADULT; ARTICLE; BRAIN ISCHEMIA; CARDIOVASCULAR RISK; COHORT ANALYSIS; CONGESTIVE HEART FAILURE; DIABETIC PATIENT; FEMALE; HAZARD RATIO; HOSPITALIZATION; HUMAN; INTENTION TO TREAT ANALYSIS; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; TREATMENT OUTCOME; CARDIOVASCULAR DISEASES; COMBINATION DRUG THERAPY; COMPARATIVE STUDY; COMPLICATION; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; DIABETIC CARDIOMYOPATHIES; ELECTRONIC HEALTH RECORD; FOLLOW UP; MIDDLE AGED; MYOCARDIAL INFARCTION; ORAL DRUG ADMINISTRATION; PUBLIC HEALTH; RETROSPECTIVE STUDY; RISK; TAIWAN;

ADMINISTRATION, ORAL; CARDIOVASCULAR DISEASES; COHORT STUDIES; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; DIABETIC CARDIOMYOPATHIES; DRUG THERAPY, COMBINATION; ELECTRONIC HEALTH RECORDS; FEMALE; FOLLOW-UP STUDIES; GLYCOSIDE HYDROLASE INHIBITORS; HUMANS; HYPOGLYCEMIC AGENTS; MALE; METFORMIN; MIDDLE AGED; MYOCARDIAL INFARCTION; NATIONAL HEALTH PROGRAMS; RETROSPECTIVE STUDIES; RISK; TAIWAN;

EID: 84945456985     PISSN: 07423071     EISSN: 14645491     Source Type: Journal    
DOI: 10.1111/dme.12800     Document Type: Article

References (34)

1. Emerging Risk Factors Collaboration, Sarwar N, Gao P, Seshasai SR, Gobin R, Kaptoge S et al. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. Lancet 2010; 375: 2215-2222.
2. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008; 359: 1577-1589.
3. Kooy A, de Jager J, Lehert P, Bets D, Wulffelé MG, Donker AJ et al. Long-term effects of metformin on metabolism and microvascular and macrovascular disease in patients with type 2 diabetes mellitus. Arch Intern Med 2009; 169: 616-625.
4. Roussel R, Travert F, Pasquet B, Wilson PW, Smith SC Jr, Goto S et al. Reduction of Atherothrombosis for Continued Health (REACH) Registry Investigators. Metformin use and mortality among patients with diabetes and atherothrombosis. Arch Intern Med 2010; 170: 1892-1899.
5. Evans JM, Ogston SA, Emslie-Smith A, Morris AD. Risk of mortality and adverse cardiovascular outcomes in type 2 diabetes: a comparison of patients treated with sulfonylureas and metformin. Diabetologia 2006; 49: 930-936.
6. Pantalone KM, Kattan MW, Yu C, Wells BJ, Arrigain S, Jain A et al. The risk of developing coronary artery disease or congestive heart failure, and overall mortality, in type 2 diabetic patients receiving rosiglitazone, pioglitazone, metformin, or sulfonylureas: a retrospective analysis. Acta Diabetol 2009; 46: 145-154.
7. McAfee AT, Koro C, Landon J, Ziyadeh N, Walker AM. Coronary heart disease outcomes in patients receiving antidiabetic agents. Pharmacoepidemiol Drug Saf 2007; 16: 711-725.
8. UK Prospective Diabetes Study UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34. Lancet 1998; 352: 854-865.
9. Lin CC, Lai MS, Syu CY, Chang SC, Tseng FY. Accuracy of diabetes diagnosis in health insurance claims data in Taiwan. J Formos Med Assoc 2005; 104: 157-163.
10. Cheng CL, Lee CH, Chen PS, Li YH, Lin SJ, Yang YH. Validation of Acute Myocardial Infarction Cases in the National Health Insurance Research Database in Taiwan. J Epidemiol 2014; 24: 500-507.
11. Hsieh CY, Chen CH, Li CY, Lai ML. Validating the diagnosis of acute ischemic stroke in a National Health Insurance claims database. J Formos Med Assoc 2015; 114: 254-259.
12. Danaei G, Rodríguez LA, Cantero OF, Logan R, Hernán MA. Observational data for comparative effectiveness research: an emulation of randomised trials of statins and primary prevention of coronary heart disease. Stat Methods Med Res 2011; 22: 70-96.
13. Hernán MA, Alonso A, Logan R, Grodstein F, Michels KB, Willett WC et al. Observational studies analyzed like randomized experiments: an application to postmenopausal hormone therapy and coronary heart disease. Epidemiology 2008; 19: 766-779.
14. Goldner MG, Knatterud GL, Prout TE. Effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes. 3. Clinical implications of UGDP results. JAMA 1971; 218: 1400-1410.
15. Cleveland JC Jr, Meldrum DR, Cain BS, Banerjee A, Harken AH. Oral sulfonylurea hypoglycemic agents prevent ischemic preconditioning in human myocardium. Two paradoxes revisited. Circulation 1997; 96: 29-32.
16. ADVANCE Collaborative Group, Patel A, MacMahon S, Chalmers J, Neal B, Billot L et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008; 358: 2560-2572.
17. Schramm TK, Gislason GH, Vaag A, Rasmussen JN, Folke F, Hansen ML et al. Mortality and cardiovascular risk associated with different insulin secretagogues compared with metformin in type 2 diabetes, with or without a previous myocardial infarction: a nationwide study. Eur Heart J 2011; 32: 1900-1908.
18. Esposito K, Giugliano D, Nappo F, Marfella R; Campanian Postprandial Hyperglycemia Study Group. Regression of carotid atherosclerosis by control of postprandial hyperglycemia in type 2 diabetes mellitus. Circulation 2004; 110: 214-219.
19. Yngen M, Ostenson CG, Hjemdahl P, Wallén NH. Meal-induced platelet activation in Type 2 diabetes mellitus: effects of treatment with repaglinide and glibenclamide. Diabet Med 2006; 23: 134-140.
20. Schmoelzer I, Wascher TC. Effect of repaglinide on endothelial dysfunction during a glucose tolerance test in subjects with impaired glucose tolerance. Cardiovasc Diabetol 2006; 5: 9.
21. Manzella D, Grella R, Abbatecola AM, Paolisso G. Repaglinide administration improves brachial reactivity in type 2 diabetic patients. Diabetes Care 2005; 28: 366-371.
22. Donahue RP, Abbott RD, Reed DM, Yano K. Postchallenge glucose concentration and coronary heart disease in men of Japanese ancestry. Honolulu Heart Program. Diabetes 1987; 36: 689-692.
23. Meigs JB, Nathan DM, D'Agostino RBSr, Wilson PW; Framingham Offspring Study. Fasting and postchallenge glycemia and cardiovascular disease risk: the Framingham Offspring Study. Diabetes Care 2002; 25:1845-1850.
24. The DECODE study group. Glucose tolerance and mortality: comparison of WHO and American Diabetes Association diagnostic criteria. Lancet 1999; 354: 617-621.
25. Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M; STOP-NIDDM Trial Research Group. Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial. JAMA 2003; 290: 486-494.
26. Hanefeld M, Chiasson JL, Koehler C, Henkel E, Schaper F, Temelkova-Kurktschiev T. Acarbose slows progression of intima-media thickness of the carotid arteries in subjects with impaired glucose tolerance. Stroke 2004; 35: 1073-1078.
27. Hanefeld M, Cagatay M, Petrowitsch T, Neuser D, Petzinna D, Rupp M. Acarbose reduces the risk for myocardial infarction in type 2 diabetic patients: meta-analysis of seven long-term studies. Eur Heart J 2004; 25: 10-16.
28. Dormandy JA, Charbonnel B, Eckland DJ, Erdmann E, Massi-Benedetti M, Moules IK et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 2005; 366: 1279-1289.
29. Lincoff AM, Wolski K, Nicholls SJ, Nissen SE. Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials. JAMA 2007; 298: 1180-1188.
30. Mannucci E, Monami M, Lamanna C, Gensini GF, Marchionni N. Pioglitazone and cardiovascular risk. A comprehensive meta-analysis of randomized clinical trials. Diabetes Obes Metab 2008; 10: 1221-1238.
31. Scirica BM, Bhatt DL, Braunwald E, Steg PG, Davidson J, Hirshberg B et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med 2013; 369: 1317-1326.
32. White WB, Cannon CP, Heller SR, Nissen SE, Bergenstal RM et al. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med 2013; 369: 1327-1335.
33. Green JB, Bethel MA, Paul SK, Ring A, Kaufman KD, Shapiro DR et al. Rationale, design, and organization of a randomized, controlled Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS) in patients with type 2 diabetes and established cardiovascular disease. Am Heart J 2013; 166: 983-989.
34. Rosenstock J, Marx N, Kahn SE, Zinman B, Kastelein JJ, Lachin JM et al. Cardiovascular outcome trials in type 2 diabetes and the sulphonylurea controversy: rationale for the active-comparator CAROLINA trial. Diab Vasc Dis Res 2013; 10: 289-301.